BioViva aims to provide regenerative medicine to the masses through gene and cell therapies. It is our intention to quickly, affordably, and safely bring these life
saving interventions to the world at large as soon as possible. Our doctors and staff will provide state of the art care in a friendly and comfortable environment. By addressing biological aging
itself, BioViva will be addressing disease at large.
Merging 21st century knowledge of regenerative biology, evolutionary medicine, and complex systems, Bioquark’s core program focuses on developing a novel class of substances termed combinatorial biologics, which take a unique approach to reversing underlying disease, degeneration or aging processes, as opposed to only effecting the symptoms of such conditions.
Calico is a research and development company whose mission is to harness advanced technologies to increase our understanding of the biology that controls lifespan. We will use that knowledge to devise interventions that enable people to lead longer and healthier lives. Executing on this mission will require an unprecedented level of interdisciplinary effort and a long-term focus for which funding is already in place.
Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CAR T-cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 16 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life science focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS).
We provide the leading edge platform of three-dimensional organ regeneration using our revolutionary bio 3D printer, Regenova. Regenova is a novel robotic system that facilitates the fabrication of three- dimensional cellular structures by placing cellular spheroids in fine needle arrays, “Kenzan method”, according to pre-designed 3D data.
Editas Medicine is a transformative genome editing company founded by world leaders in the fields of genome editing, protein engineering, and molecular and structural biology, with specific expertise in CRISPR/Cas9 and TALENs technologies. The company's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.
Human Longevity Inc. (HLI) is a genomics and cell therapy-based diagnostic and therapeutic company. Using advances in genomic sequencing, the human microbiome, proteomics, informatics, computing, and cell therapy technologies, HLI is building the world’s most comprehensive database on human genotypes and phenotypes to tackle the diseases associated with aging-related human biological decline. HLI is also leading the development of cell-based therapeutics to address age-related decline in endogenous stem cell function. HLI is concentrating on cancer, diabetes and obesity, heart and liver diseases, and dementia.
At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.
Through excellence in knowledge management, machine learning and bioinformatics, relentless pursuit for new drug, omics and clinical outcomes data, development of reliable in silico drug screening methods, novel validation approaches and strong international partnerships in personalized medicine we strive to find real working solutions to cure and prevent age-related diseases and aging itself.
At Organovo, we design and create functional human tissues using our proprietary three-dimensional bioprinting technology. Our goal is to build living human tissues that are proven to function like native tissues. With reproducible 3D tissues that accurately represent human biology, we are enabling ground-breaking therapies.
RetroSense Therapeutics is a biotechnology company that is developing a game-changing gene therapy to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved therapies to improve or restore vision in patients with these retinal degenerative conditions.
Spark is a leader in the field of gene therapy, seeking to transform the lives of patients by developing potential one-time, life-altering treatments for debilitating genetic diseases. We initially are applying our integrated platform, which was developed over two decades at The Children’s Hospital of Philadelphia, or CHOP, to treat rare diseases where no, or only palliative, therapies exist.
The gene therapy vectors used in our programs are engineered using an adeno-associated virus, or AAV, which is a small, non-pathogenic virus. Our viral vectors are designed to encapsulate a therapeutic gene sequence and have been demonstrated to be effective vehicles for delivering genetic material into target cells, providing unique advantages over alternative therapeutic approaches.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. We have five approved products on the market today and are relentless in our pursuit of “medicines for life”®.
This is a non-commercial, not-for-profit website. The content is provided for information purposes only and does not claim to be complete.
Disclaimer: All content is quoted from public websites of the respective entities or Wikipedia. Miriam Leis is not responsible for any incorrect information on the original websites of the entities listed. It can also not be guaranteed that all information listed here is always up to date. Although great care is being taken to provide good quality entries and information, Miriam Leis is not responsible for the quality and performance of the listed entities, nor is any particular endorsement of a listed entity intended.
Responsible for content: Miriam Leis
Contact: leis.miriam [at] gmail.com or use this contact form.
Location: European Union